| API Products in R&D | THERAPEUTIC CATEGORY | STATUS |
|---|---|---|
| Darolutamide | Oncology | Developed |
| Elacestrant | Oncology | Under developed |
| Exemestane | Oncology | Under developed |
| Osimertinib | Oncology | Under developed |
| Resmetirom | NASH | Under developed |
| Everolimus | Oncology | Developed |
| Umeclidinium Bromide | COPD | Pilot |
| Vilanterol | COPD | Pilot |
| Rimegepant | Migraine Headache | Pilot |
| Vibegron | Overactive Bladder (OAB) | Pilot |
| Semaglutide | Anti-diabetic | Pilot |
| Tirzepatide | Anti-diabetic | Under development |
| Vosortide | Achondroplasty | Under developed |
| Inclisiran | Hyperlipidemia(siRNA) | Under development |
| Nusinersen Sodium | SMA(ASO) | Pilot |
| Risdiplam | SMA | Under development |
| Vutrisiran | hATTR/whATTR(siRNA) | Under development |
| Filgotinib | Rheumatoid arthritis(JAK1) | Developed |
| Upadacitinib | Rheumatoid arthritis(JAK1) | Under development |
| Finerenone | CKD | pilot |
| Estetrol | Estrogen | Under development |
| Progesterone | Estrogen | Under development |
| Methylprednisolone | Anti-inflammatory | Under development |
|
Zuranolone |
MDD&PPD |
Under development |
※ Disclaimer:
Products protected by valid patents in this list are for laboratory analytical/research purposes only and are not offered for sale in countries or area wherethe sale of such products constitutes a patent infringement.Any liability is at buyer's risk.
Follow Aoruite WeChat official account